Myolex, Inc.
Brookline, MA
- UEI
- XMRNG2MNK6F1
- CAGE
- 5L0H4
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 1309 Beacon St #300, Brookline, MA 02446, USA
- Website
- myolex.com
- Founded
- 2009
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- SIC code
- 38 Instruments & Related Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Rytek Medical Inc. | Lebanon, NH | — |
| 3DT Holdings, LLC | San Diego, CA | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Medical Device R&D | San Francisco, CA | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| A M E C | — | 541330 Engineering Services |
| Algometrx Inc. | Washington, DC | — |
About the company
Myolex, Inc. is a minority-owned, Hispanic American-owned corporate entity based in Brookline, Massachusetts, focused on developing advanced medical technology centered on Electrical Impedance Myography (EIM). The company specializes in creating innovative, non-invasive medical diagnostic technologies that leverage electrical current measurement techniques to assess muscle health and condition across various medical contexts. Registered in SAM.gov since 2009, Myolex has positioned itself as a technology development firm with a primary focus on creating advanced diagnostic tools for muscle-related medical assessments.
Through federal grant awards, Myolex has consistently secured funding from multiple National Institutes of Health (NIH) agencies, including the National Cancer Institute, National Institute on Aging, and National Institute of Arthritis and Musculoskeletal and Skin Diseases. The company's grant-funded research has concentrated on developing its proprietary MSCAN device and EIM technology to address critical medical challenges such as cancer cachexia, sarcopenia in older adults, acute compartment syndrome, and muscle condition assessment in various myopathic disorders. Each project involves developing machine learning algorithms and cloud-based platforms to interpret EIM data, with the overarching goal of providing convenient, cost-effective alternatives to traditional imaging techniques like MRI. The grants, ranging from $263,052 to support cancer research to projects focused on muscle health in aging and trauma, demonstrate Myolex's commitment to advancing medical diagnostics through innovative electrical impedance technology.
Quick answers
Is Myolex, Inc. registered in SAM.gov?
Yes. Myolex, Inc.'s SAM.gov registration is active through September 10, 2027.
What is Myolex, Inc.'s most recent federal award?
Myolex, Inc.'s most recent federal grant award is Electrical impedance myography (EIM) to detect and track cancer cachexia (R43CA306431), from National Cancer Institute (NIH), on September 1, 2025.
On GovTribe
See Myolex, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors